FATE News and Press, Fate Therapeutics Inc. From 05/19/25

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. Unfortunately, relapsed/refractory CD33 expressing hematologic mal...

2025-05-13 17:54:36 ET More on Fate Therapeutics Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector Fate Therapeutics gets RMAT status from FDA for lupus treatment Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earni...

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine Advanced Therapy Designation Granted by the FDA for FT819 in Moderate-to...

2025-05-08 18:22:50 ET Summary I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determine if the market's lack of interest is justified ...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients, today announced that five presenta...

2025-04-14 11:34:06 ET More on Fate Therapeutics Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for...

–   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process –   RMAT review by FDA included initial clinical safety and activity data from ongoin...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more urgent. Statista forecasts a 20% increase in new cancer cases by...

2025-03-05 16:51:06 ET More on Fate Therapeutics Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for...